Sleep & Neurological Peptides: Research Compounds for Neuroscience Studies

DSIP (Delta Sleep-Inducing Peptide) was first isolated in 1977 from the cerebral venous blood of rabbits during electrically induced sleep. The original research observed that injection of the purified peptide into recipient rabbits produced an increase in delta-wave EEG activity — the slow-wave pattern associated with deep sleep stages. Subsequent studies in rodent models have examined DSIP's interactions with stress-response systems, opioid receptor pathways, and circadian rhythm regulation, though its precise mechanism of action remains an active area of investigation.

Semax has been studied primarily in Russian research institutions, where published work has examined its effects on brain-derived neurotrophic factor (BDNF) expression, serotonin and dopamine metabolism, and cognitive performance metrics in animal behavioral models. A notable characteristic of Semax research is its structural relationship to ACTH(4-10) — the peptide retains the signaling fragment of adrenocorticotropic hormone but with modifications designed to alter its receptor interaction profile and extend its stability.

Selank research has focused on the peptide's observed anxiolytic-like effects in animal behavioral models — including elevated plus maze and open field tests — and its interactions with the GABAergic system. Published studies have examined whether Selank modulates GABA receptor subunit expression and benzodiazepine binding site activity in rodent brain tissue. Its structural basis is tuftsin, an endogenous immunomodulatory tetrapeptide, with an added tripeptide (Pro-Gly-Pro) tail that alters its pharmacokinetic profile.

The overlap between sleep, neurological, and immune signaling pathways is a recurring theme in this peptide category. Both Semax and Selank have been studied for immunomodulatory effects alongside their neuroscience applications, reflecting the increasingly recognized cross-talk between nervous and immune system signaling.